ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
The super-resolution optical technology will accelerate discovery in biomedical research and transform in vitro diagnostics
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
The companies will spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Subscribe To Our Newsletter & Stay Updated